Company Overview - Odyssey Health, Inc. is a medical technology company focused on life-saving medical solutions and aims to create, acquire, and accumulate distinct assets and technologies that provide meaningful medical solutions [6] - Odyssey Medical Devices, Inc. is a wholly owned subsidiary of Odyssey Health, Inc. [6] Product Announcement - Odyssey Health has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a non-invasive test for breast abnormalities [1] - The BreastCheck® test can be performed at home in just 15 minutes, providing immediate results and serving as an effective first-line screening device [2][4] Market Context - The breast cancer diagnostics market is rapidly growing, currently valued in the low tens of billions of dollars, with forecasts to double or more over the next 8-10 years [3] - Early detection has significantly increased breast cancer survival rates, with an estimated 317,000 new cases of invasive breast cancer expected to be diagnosed in women in the U.S. this year [3][5] Technology and Regulatory Status - The technology behind BreastCheck® is FDA registered in the U.S. and also registered with relevant regulatory authorities in the European Union and the United Kingdom [2] - BreastCheck® is designed to be an adjunct to established procedures for breast disease detection, such as clinical breast examinations and mammography [4] Future Outlook - The company expects to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking a transition from a development-stage to a revenue-generating medtech company [3]

Core Insights - RadNet, Inc. has partnered with Regal Medical Group, Lakeside Community Healthcare, and ADOC Medical Group to include its AI-powered Early Breast Cancer Detection (EBCD) program in their health plans, enhancing access to advanced diagnostic services for patients [1][3][7] Group 1: Partnership and Program Implementation - The medical groups involved are located in Southern California, covering counties such as Los Angeles, Ventura, Orange, San Bernardino, Riverside, and San Diego, and will provide EBCD services to all eligible mammogram patients [2][7] - RadNet will initiate a patient outreach program to improve compliance with annual mammography screening guidelines by actively contacting eligible patients [2][3] Group 2: Commitment to Early Detection - Dr. Howard Berger, CEO of RadNet, emphasized the importance of early breast cancer detection, noting that one in eight women will develop breast cancer in their lifetime, making early detection critical for optimal treatment [3] - The EBCD program aims to detect breast cancer earlier than traditional methods, potentially reducing treatment needs and improving patient outcomes [3][4] Group 3: Impact on Patient Care - Will Jukes, Senior VP of Regal Medical Group, stated that the EBCD program will enhance early cancer detection and streamline the screening process, positively affecting patient outcomes [4] - The collaboration is expected to increase annual compliance with screening guidelines, showcasing a commitment to innovative healthcare solutions [4][7] Group 4: Market Position and Reach - RadNet operates a network of 401 outpatient imaging centers across several states, including California, and is a leading provider of diagnostic imaging services in the U.S. [8] - The partnership with major health insurance carriers will expand access to quality care for nearly 600,000 members in Southern California [7][8]